(Q51022840)

English

Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.

scientific article published on 8 December 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey. (English)

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

author name string

Morgane Beck

1

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

Bruno Michel

2

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

Marie-Christine Rybarczyk-Vigouret

3

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

Dominique Levêque

4

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

Christelle Sordet

5

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

Jean Sibilia

6

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

Michel Velten

7

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

publication date

8 December 2016

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

Monoclonal Antibodies

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

9

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

2

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

383-390

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Biosimilars: How Can Payers Get Long-Term Savings?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Biosimilars for the management of rheumatoid arthritis: economic considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Biosimilar regulation in the EU.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Assessment of pharmacists' views on biosimilar naming conventions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Biosimilar insulins: a European perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Biosimilars: the science of extrapolation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Barriers to the uptake of biosimilars and possible solutions: a Belgian case study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Biosimilars: Implications for health-system pharmacists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Biosimilars: what clinicians should know

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

The US approach to biosimilars: the long-awaited FDA approval pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

22 May 2018

Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

14 August 2018

Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

14 August 2018

Biosimilars in rheumatology: the wind of change

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5297517

14 August 2018

Biosimilars: from technical to pharmacoeconomic considerations. 30th Rencontres Nationales de Pharmacologie et Recherche clinique pour l'Innovation et l'Evaluation des Technologies de Santé. Tables rondes

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2016.1267087

21 January 2018

Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27929743

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations

1 reference

https://pubmed.ncbi.nlm.nih.gov/27929743

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First monoclonal antibody biosimilars: tackling the challenge of substitution

1 reference

https://pubmed.ncbi.nlm.nih.gov/27929743

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biosimilars: from Technical to Pharmacoeconomic Considerations

1 reference

https://pubmed.ncbi.nlm.nih.gov/27929743

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27929743

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1080/19420862.2016.1267087

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

1 reference

Europe PubMed Central

27 March 2018

http://europepmc.org/abstract/PMC/5297517

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51022840&oldid=1458102127"